Pharma Pulse 6/19/25: Strategic Planning in the Rebate Economy; The Truth About AI Adoption Speed in Clinical Research
Strategic Planning in the Rebate Economy: What Pharma Must Do Now
A recent Pharmaceutical Executive article outlines how, despite decades of evolving policy from OBRA ’90 to the Inflation Reduction Act, the US pharmaceutical system remains deeply reliant on manufacturer rebates—prompting drugmakers to shift from workaround tactics to strategic execution in order to thrive in today’s rebate-driven environment while preparing for a more transparent, reform-ready future.
2025 DIA Global Annual Meeting: The Truth About AI Adoption Speed in Clinical Research
In an interview with Applied Clinical Trials at the 2025 DIA Global Annual Meeting, Emmes CEO Peter Ronco highlighted how the public sector—especially the NIH and FDA—is quietly leading AI innovation in clinical research, debunking myths about automation and emphasizing that while AI is advancing faster than expected, human oversight and cultural adaptation remain essential to unlocking its full potential.
Precision medicine oncology pharmacists are playing an increasingly vital role in cancer care by helping match patients to targeted therapies, managing access barriers, monitoring for toxicities, and educating patients—ensuring safer, more effective treatment as precision oncology continues to expand in clinical practice.
In a recent episode of How This Is Building Me, breast surgeon and breast cancer survivor Liz O'Riordan, FRCS, PhD, spoke with D. Ross Camidge about how her personal journey with cancer reshaped her mission to educate medical colleagues and empower patients through open dialogue.
Kennedy's New US Vaccine Panel to Discuss Measles Shot for Children
A newly restructured US vaccine advisory panel will meet later this month to discuss the safety of thimerosal-containing flu shots and combined MMRV vaccines for children—two topics long promoted by Health Secretary Robert F. Kennedy Jr., despite overwhelming scientific evidence disproving links to brain damage or autism—raising concerns among experts about the politicization of vaccine policy and the omission of COVID-19 booster guidance from the agenda.
